New hope for tough prostate cancer: immunotherapy meets targeted radiation
NCT ID NCT05682443
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether adding an immunotherapy drug (ONC-392) to a targeted radiation therapy (Pluvicto) can help men with a hard-to-treat form of advanced prostate cancer. About 148 participants whose cancer has worsened despite standard treatments will receive either a low or high dose of ONC-392 plus Pluvicto. The goal is to see if the combination can shrink tumors or delay cancer growth, while monitoring for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ONC-392 (gotistobart) and lutetium Lu 177 vipivotide tetraxetan (Pluvicto)
What this could lead to
If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies, potentially slowing disease progression.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply broadly. The combination may cause significant side effects, including immune-related reactions and radiation toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chesapeake Urology Research Associates
Towson, Maryland, 21204, United States
-
Columbia University Irving Cancer Center
New York, New York, 10032, United States
-
Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Emory University Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Lahey Hospital & Medical Center
Burlington, Massachusetts, 01805, United States
-
Moffitt Cancer Cancer
Tampa, Florida, 33612, United States
-
NYU Langone Health, Laura & Isaac Perlmutter Cancer Center
New York, New York, 10016, United States
-
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, 87109, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97210, United States
-
Oncology and Hematology Associates Of Southwest Virginia USOR
Norton, Virginia, 24273, United States
-
Rocky Mountain Cancer Centers USOR
Aurora, Colorado, 80012, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14203, United States
-
Rutgers Cancer Institute
New Brunswick, New Jersey, 08901, United States
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21202, United States
-
UC Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
UNC North Carolina Comprehensive Cancer Care Center
Chapel Hill, North Carolina, 27514, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
-
UW Carbone Cancer Center
Madison, Wisconsin, 53792, United States
-
University of Mississippi Medical Center
Jackson, Mississippi, 39216, United States
-
Virginia Cancer Specialists USOR
Fairfax, Virginia, 22031, United States
-
Virginia Oncology Associates USOR
Norfolk, Virginia, 23502, United States
-
XCancer/GU Research Network
Omaha, Nebraska, 68130, United States